Correction of liver functional state in patients with autoimmune thyroid diseases

Main Article Content

V.I. Pankiv

Abstract

The lecture describes the correlation between autoimmune thyroid diseases and liver functional state. The comprehensive method for the treatment of these patients using ursodeoxycholic acid (Ursofalk) is described. Author’s experience of Ursofalk application allows recommending the preparation at a dose 15 mg/kg body weight daily divided into three doses, during three months, in patients with autoimmune thyroid diseases.

Article Details

How to Cite
Pankiv, V. “Correction of Liver Functional State in Patients With Autoimmune Thyroid Diseases”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 14, no. 5, Oct. 2018, pp. 499-02, doi:10.22141/2224-0721.14.5.2018.142687.
Section
Lecture

References

Vanderpump MPJ. The epidemiology of thyroid diseases. In: Braverman LE, Utiger RD (eds).Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text, 9th ed. JB Lippincott-Raven: Philadelphia; 2005. 398-496 pp.

McGrogan A, Seaman HE, Wright JW, de Vries CS. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol (Oxf). 2008 Nov;69(5):687-96. doi: 10.1111/j.1365-2265.2008.03338.x.

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi: 10.1089/thy.2016.0229.

Pasyechko NV, Kuleshko II, Kulchinska VM, et al. Ultrastructural liver changes in the experimental thyrotoxicosis. Pol J Pathol. 2017;68(2):144-147. doi: 10.5114/pjp.2017.69690.

Kubota S, Amino N, Matsumoto Y, et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves’ disease and painless thyroiditis. Thyroid. 2008;18(3):283-287. doi:10.1089/thy.2007.0189.

Burra P. Liver abnormalities and endocrine diseases. Best Pract Res Clin Gastroenterol. 2013;27(4):553-563. doi:10.1016/j.bpg.2013.06.014.

de Campos Mazo DF, de Vasconcelos GB, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol. 2013;6:9-17. doi: 10.2147/CEG.S39358.

Khemichian S, Fong TL. Hepatic dysfunction in hyperthyroidism. Gastroenterol Hepatol (NY). 2011;7(5):337-339.

Shetty S, Rajasekaran S, Venkatakrishnan L. Grave’s disease and primary biliary cirrhosis – an unusual and challenging association. J Clin Exp Hepatol. 2014;4(1):66-67. doi:10.1016/j.jceh.2013.08.001.

Jhummon NP, Tohooloo B, Qu S. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease. Thyroid Res. 2013;6:4. doi:10.1186/1756-6614-6-4.

Sarkhy A, Persad R, Tarnopolsky M. Muscle weakness in a girl with autoimmune hepatitis and Graves’ disease. Eur J Pediatr. 2009;168(2):241-243. doi:10.1007/s00431-008-0738-6.

Barzilay-Yoseph L, Shabun A, Shilo L, Hadary R, Nabriski D, Kitay-Cohen Y. Thyrotoxic hepatitis. Isr Med Assoc J. 2011;13(7):448-450.

Breidert M, Offensperger S, Blum HE, Fischer R. Weight loss and severe jaundice in a patient with hyperthyroidism. Z Gastroenterol. 2011;49(9):1267-1269. doi:10.1055/s-0029-1246059.

Pikulev DV, Klemenov AV. Thyrotoxic hepatitis. Problemi Endocrinologii. 2017;63(1):46-50. doi: 10.14341/probl201763137-41. (in Russian).

Xiang Z, Chen YP, Ma KF, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. doi: 10.1186/1471-230X-13-140.

Zhuravleva LV, Krivonosova EM. Comparative characteristics of hepatoprotective drugs

is the key for their rational use. Sucasna gastroenterologia. 2013;4(72):93-101. (in Russian).

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 > >>